42% of young women who undergo chemotherapy develop ovarian failure
42% of young women who have received chemo- or radiation therapy develop early ovarian failure before age 30, while 20% of cases of breast cancer are hereditary. These are some of the facts that the Scientific Committee of Dexeus Women’s Health provided today, following a review of the advances made in the treatment of this disease in women on the occasion of World Cancer Day, which is celebrated tomorrow.
The Committee stressed that the advent of new diagnostic and treatment approaches has improved the quality of life of women who have overcome cancer. "Genetic tests have increased the detection of genetic mutations by 10%, and allow to customise treatment", explained Dr. Rafael Fábregas, Gynaecological Oncology and Mastology Consultant at Dexeus Women's Health.
According to the Committee, one of the after-effects of chemotherapy is that some of the drugs used induce early menopause, with consequent fertility problems. Many women are unaware of this risk, which is why experts stress the importance of addressing this issue very early on.
While in the 70s, the aim was to increase the survival rate, the current priority is to improve the quality of life of the patients. "Some techniques are now available which are allowing us to achieve this goal, including the addition of an adjuvant treatment which helps prevent future recurrences, oncoplastic surgery, or fertility preservation in young women", adds Dr. Fábregas.